Cost-Effectiveness of Treating Upper Limb Spasticity Due to Stroke with Botulinum Toxin Type A: Results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial
Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources. This study compared the cost-effectiveness of treating post-stroke upper limb spasticity with botulinum toxin type A plus an upper limb therapy programme against the therapy programme alone. Data on resource use and health outcomes were prospectively collected for 333 patients with post-stroke upper limb spasticity taking part in a randomized trial and combined to estimate the incremental cost per quality adjusted life year (QALY) gained of botulinum toxin type A plus therapy relative to therapy alone. The base case incremental cost-effectiveness ratio (ICER) of botulinum toxin type A plus therapy was ￡93,500 per QALY gained. The probability of botulinum toxin type A plus therapy being cost-effective at the England and Wales cost-effectiveness threshold value of ￡20,000 per QALY was 0.36. The point estimates of the ICER remained above ￡20,000 per QALY for a range of sensitivity analyses, and the probability of botulinum toxin type A plus therapy being cost-effective at the threshold value did not exceed 0.39, regardless of the assumptions made.
References
[1]
Youman, P.; Wilson, K.; Harraf, F.; Kalra, L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003, 21, 43–50.
[2]
Evers, S.M.A.A.; Struijs, J.N.; Ament, A.J.H.A.; van Genugten, M.L.L.; Jager, J.H.C.; van den Bos, G.A.M. International comparison of stroke cost studies. Stroke 2004, 35, 1209–1215, doi:10.1161/01.STR.0000125860.48180.48.
[3]
Saka, O.; McGuire, A.; Wolfe, C. Cost of stroke in the United Kingdom. Age Ageing 2009, 38, 27–32.
[4]
Reducing Brain Damage: Faster Access to Better Stroke Care; National Audit Office: London, UK, 2005.
[5]
Intercollegiate Stroke Working Party. National Clinical Guideline for Stroke, 3rd ed.; Royal College of Physicians: London, UK, 2008.
[6]
Spasticity in Adults: Management Using Botulinum Toxin: National Guidelines; Royal College of Physicians: London, UK, 2009.
[7]
Dolly, J.O.; Aoki, K.R. The structure and mode of action of different botulinum toxins. Eur. J. Neurol. 2006, 13, 1–9, doi:10.1111/j.1468-1331.2006.01648.x.
[8]
Garces, K.; McCormick, A.; McGahan, L.; Skidmore, B. Botulinum Toxin A for Upper and Lower Limb Spasticity: A Systematic Review; (Technology report no 51) Canadian Coordinating Office for Health Technology Assessment: Ottawa, Canada, 2005.
[9]
Hesse, S.; Reiter, F.; Konrad, M.; Jahnke, M.T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: A randomized, double-blind, placebo-controlled trial. Clin. Rehabil. 1998, 12, 381–388, doi:10.1191/026921598668275996.
[10]
Bhakta, B.B.; Cozens, J.A.; Chamberlain, M.A.; Bamford, J.M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial. J. Neurol. Neurosurg. Psychiatry 2000, 69, 217–221, doi:10.1136/jnnp.69.2.217.
[11]
Brashear, A.; Gordon, M.F.; Elovic, E.; Kassicieh, V.D.; Marciniak, C.; Do, M.; Lee, C.H.; Jenkins, S.; Turkel, C. Botox post-stroke spasticity study group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N. Engl. J. Med. 2002, 347, 395–400, doi:10.1056/NEJMoa011892.
[12]
Shaw, L.; Price, C.; van Wijck, F.; Shackley, P.; Steen, N.; Barnes, M.; Ford, G.; Graham, L.; Rodgers, H. Botulinum toxin for the upper limb after stroke (BoTULS) trial: Effect upon impairment, activity limitation and pain. Stroke 2011, 42, 1371–1379.
[13]
Guide to the Methods of Technology Appraisal; National Institute for Clinical Excellence: London, UK, 2004.
[14]
Curtis, L. Unit Costs of Health and Social Care; PSSRU,University of Kent: Canterbury,UK, 2007.
[15]
British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 53; BMJ Publishing Group Ltd and RPS Publishing: London, UK, 2007.
[16]
Brooks, R. EuroQol: The current state of play. Health Policy 1996, 37, 53–72, doi:10.1016/0168-8510(96)00822-6.
[17]
Dolan, P. Modeling valuations for EuroQol health states. Med. Care 1997, 35, 1095–108, doi:10.1097/00005650-199711000-00002.
[18]
Richardson, G.; Manca, A. Calculation of quality adjusted life years in the published literature: A review of methodology and transparency. Health Econ. 2004, 13, 1203–1210, doi:10.1002/hec.901.
[19]
O’Brien, B.; Briggs, A.H. Analysis of uncertainty in health care cost-effectiveness studies: An introduction to statistical issues and methods. Stat. Methods Med. Res. 2002, 11, 455–468.
[20]
Schafer, J.L. Analysis of Incomplete Multivariate Data; Chapman and Hall: London, UK, 1997.
[21]
Rawlins, M.D.; Culyer, A.J. National institute for clinical excellence and its value judgments. BMJ 2004, 329, 224–227, doi:10.1136/bmj.329.7459.224.
[22]
Ward, A.; Roberts, G.; Warner, J.; Gillard, S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J. Rehabil. Med. 2005, 37, 252–257.
